Biologically Inspired Engineering, synbio, synthetic biology, crispr
Aardvark Therapeutics, a San Diego-based biotech company, is on track for an initial public offering (IPO) this summer. The company is developing a weight loss pill, ARD-101, that has shown promise in early-stage trials. ARD-101 works differently from other weight loss drugs by targeting two gut hormones, GLP-1 and CCK, which could potentially reduce side … Read more
In the transformative landscape of healthcare, the rise of weight-loss medications such as Ozempic and Wegovy has sparked a cultural and business revolution, challenging our perceptions of obesity and medical treatment. These drugs, originally designed for type 2 diabetes management, have unexpectedly become a beacon for those seeking weight loss solutions, leading to a societal … Read more
In recent groundbreaking research, scientists have discovered that the drug Dulaglutide, commonly used to type 2 diabetes mellitus (T2DM), has shown promising results in reversing depression-like behavior and restoring metabolic balance in the hippocampus of mice subjected to chronic mild stress. This study highlights the intricate link between metabolic disorders and mental health, suggesting a … Read more
In biotech investing, distilling exceptional opportunities from the average (or worse) ventures requires a keen eye on insider activities, financial health, and clinical progress. Beam Therapeutics (BEAM) presents a case that demands caution, with insider stock sales, a substantial accumulated deficit, and limited clinical advancements raising significant concerns. In contrast, Intensity Therapeutics (INTS) is an … Read more
Cancer remains one of the world’s leading causes of death. Traditional treatments – surgery, radiation therapy, and chemotherapy – have saved countless lives, yet their limitations are evident. Chemotherapy’s harsh side effects, the potential for recurrence after surgery, and limits to radiation use necessitate new tools in our fight against cancer. Recent breakthroughs in our … Read more
Our immune system is complex beyond comprehension. It acts as a vigilant guard, constantly patrolling for and eliminating threats like viruses, bacteria, and even abnormal cells that could turn cancerous. Cancer is a cunning adversary. New research from a collaborative effort by scientists at the Massachusetts Institute of Technology (MIT), Dana-Farber Cancer Institute, Harvard Medical … Read more
Biotech companies developing GLP-1 agonists for weight loss treatment are being keenly pursued by more mature pharmaceutical companies that have missed the bandwagon so far. This is because use of GLP-1s could increase by 10 – 70 million consumers by 2028, perhaps becoming the largest drug class in history. Reuters reports that the widespread use … Read more
There is a furious pace of innovation, deal flow and drug approvals for the new class of glucagon-like peptide 1 (GLP-1) receptor agonists and the emerging next gen Dual Agonists for the treatment of obesity and weight loss. Among mature pharmaceutics companies, the bandwagon took off when the sleepy backwater of GLP-1s for diabetes treatment … Read more
NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist. Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. … Read more
Immix Biopharma (IMMX) is CART-T cell therapy company targeting oncology and immune-dysregulated disease. Immix’s subsidiary Nexcella (94% owned) focuses a CAR-T therapy, NXC-201, which is in clinical trials for the treatment of multiple myeloma and AL amyloidosis (ALA). The company’s other promising therapy, IMX-110, is being investigated in a Phase 1b/2a study for the treatment … Read more